Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

Related News

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Content from other channels on our network

Seeq and Applied Computing partner on industrial AI for energy operations

ARENA opens Round 3 of Solar Sunshot with $250m available

Testing Profinet I/O devices without a dedicated PLC

CCEP's $39.7m can line upgrade in Perth increases capacity 40%

Cybersecurity and digitalisation for Zimbabwe platinum mine

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care

Rapid-response discharge model targets bed block

Industry transitions from gas to renewable heat: report

Boral launches detailed carbon reporting capability

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

Industrial electricity costs could halve by sharing infrastructure

All content Copyright © 2026 Westwick-Farrow Pty Ltd